44 results about "Therapy systemic" patented technology

In vivo methods are provided for using an electric field to delivery therapeutic or immunizing treatment to a subject by applying non-invasive, user-friendly electrodes to the surface of the skin. Thus, therapeutic or immunizing agents can be delivered into cells of skin for local and systemic treatments or for immunization with optimal gene expression and minimal tissue damage. In particular, therapeutic agents include naked or formulated nucleic acid, polypeptides and chemotherapeutic agents.

A semisolid therapeutic delivery system and combination semisolid, multiparticulate therapeutic delivery system for therapeutic applications is provided which includes a biocompatible semisolid delivery system and a biocompatible combination semisolid, multiparticulate delivery system for injection, deposition, or implantation within the body to facilitate local or systemic therapeutic effects through the actions of incorporated medicaments or actions inherit to the system.

This invention describes a bioerodible fibrin material which is obtained by mixing fibrinogen and thrombin reconstituted or diluted with a particular high tonic strength medium, free of calcium. Such a fibrin-based biomaterial develops a tight structure with thin fibers and small pore size suitable for use as an anti-adhesion barrier. In this invention, thrombin is no longer the variable which governs the tightness and the porosity of the fibrin material obtained, but still controls the clotting time. The mechanical behavior, high-water capacity, and releasable retention properties for therapeutic agents of this fibrin structure causes the fibrin material to be ideally suited for use as a drug delivery device, capable of delivering proteins, hormones, enzymes, antibiotics, antineoplastic agents and even cells for local and systemic treatment of human and non-human patients.

Methods and systems for the treatment for ALS incorporating stem cells harvested from the subject to be treated. These stem cells may be genetically altered with the addition of several genes of interest. Then, the patient will receive systemic gene therapy for the muscles and directed specifically at motor neurons. In this multi-pronged treatment approach, the stem cells provide immune regulation and the regeneration of motor neurons. And, the new motor neurons carry the added genes, which are protective against motor neuron death from ALS. The systemic therapy increases the amount of genes, which further reduces the effects of ALS. Additional gene therapy administered in the muscle will be further protective of the axon, while maintaining muscle mass and function.

Disclosed are pharmaceutical compositions, particularly oral dosage forms, which comprise two or more enteric coating materials, either as a coating or as part of a matrix dosage form, and methods of making and using the same. The compositions are characterized by having a sustained release profile at lower pH and an accelerated dissolution profile at higher pH.

Pharmaceutically acceptable single parasiticidal agent compositions of imidacloprid for oral delivery to mammals to systemically control targeted blood-sucking or blood-consuming parasites, such as fleas, ticks and certain species of helminthes and scabies.

Alterations of redox homeostasis in mammals underlie a host of symptoms, syndromes and diseases, including AIDS and cancer, which can be successfully treated by administration to a mammal of therapeutically-effective amounts of sulfide compounds and / or thiosulfate compounds and / or thionite compounds and / or sulfite compounds and / or thionate compounds and / or any organic, inorganic or organometallic precursors thereof. The unique compositions of this invention contain one or more “active sulfur compounds” in combination with each other or with other therapeutic agents. The invention also encompasses the varying modes of administration of the therapeutic compounds.

In vivo methods are provided for using an electric field to delivery therapeutic treatment to a subject while reducing inducement of histopathological change in the target muscle tissue, such as is associated with induction or amplification of an immune response caused by the pulsed electric field. Therapeutic agents can be delivered nto cells of muscle for local and systemic treatments with optimal gene expression and minimal tissue damage. In particular, therapeutic agents include naked or formulated nucleic acid, polypeptides and chemotherapeutic agents.

Copper ion treatments and methods of treatment are provided to treat various body conditions affecting the oral, respiratory and / or otic areas of the body. The copper ion treatments contain copper ions which bring about local and systemic therapeutic effects as a result of contacting anatomical tissue of the oral cavity, the nasal passages or ear canal. The copper ion treatments and methods involve copper ion-containing solutions, copper ion toothpaste and copper ion mouthwash. The copper ion-containing solutions can be delivered to the oral cavity by spraying or swabbing, can be delivered to the nostrils as spray, drops, or by swabbing, and can be delivered to the ear canal as spray, drops, or by swabbing. The copper ion toothpaste is used for brushing the teeth, and the copper ion mouthwash is used for rinsing the mouth.

A freezable unit dosage delivery system, method of preparation, a solid unit dosage, method of treating symptoms and conditions, and kit is disclosed. The freezable unit dosage delivery system includes a composition, preferably containing one or more medicinal ingredients, having a freezing point less than 5° C.; a storage container comprising one or more cavity, each configured to receive a unit dosage quantity of the composition; and a sealing sheet for sealing engagement with the storage container. Upon freezing, the unit dosage quantity solidifies into a solid unit dosage that may be administered one of orally, rectally or vaginally for the local or systemic treatment of symptoms and conditions in a human.

The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.

The invention relates to a postpartum rehabilitation treatment instrument, comprising a host (11), an operating console (8) and a base (12) are respectively arranged at the upper and lower ends of the host (11), and an operating keyboard (2) is symmetrically arranged on the operating console (8). ) and a push-pull slot (3), a double-sided display screen (1) is arranged between the operation keyboard (2), and a universal wheel (13) is arranged at the lower end of the base (12), and the corresponding operation on the host (11) Both sides of the keyboard (2) are also provided with an accessory storage box (7) and an accessory connection hole (6), and the inside of the host (11) is provided with a Holes (6) are connected to the control system. The invention is simple in structure, easy to use, can treat a plurality of patients at the same time, and can be connected with accessories at different parts for systemic treatment as required.

A pharmaceutical composition for application to an area of skin of a subject for local and / or systemic treatment of a COX-2 mediated disorder comprises a backing sheet that is flexibly conformable to the area of skin, the backing sheet having opposing surfaces that are respectively distal and proximal to the skin when applied; and a coating on the proximal surface of the backing sheet that comprises (a) an adhesive, (b) an active agent comprising a selective COX-2 inhibitory sulfonamide drug of low water solubility, and (c) a solvent system for the active agent, wherein the active agent is in a therapeutically effective total amount and the solvent system is selected with regard to composition and amount thereof to be effective to maintain the active agent substantially completely in solubilized form. A method of local treatment of a site of pain and / or inflammation in a subject comprises applying the composition to a skin surface of the subject, preferably at a locus overlying or adjacent to the site of pain and / or inflammation, and leaving the composition in place for a time period effective to permit delivery of a locally therapeutic amount of the active agent. A method of systemic treatment of a subject having a COX-2 mediated disorder comprises applying the composition to a skin surface of the subject, and leaving the composition in place for a time period effective to permit transdermal delivery of a therapeutic amount of the active agent.

A composition comprising a gene therapy product for use in the treatment of a dystrophic disease in a subject, advantageously in humans, wherein:—the gene therapy product comprises a nucleic acid sequence encoding a functional microdystrophin;—the composition is systemically administered.

A method and composition is provided for organ rescue wherein a specific counter-measure is applied locally to a tissue at risk for or exhibiting an adverse side effect of a cancer treatment. More particularly, the method and composition is directed at controlling Hand-Foot Syndrome, a painful redness and cracking of the skin of the hands and feet which can occur with systemic treatment with 5-fluorouracil or a precursor thereof. Uracil ointment is applied to the skin of the hands and feet to prevent Hand-Foot Syndrome which can occur from systemic administration of 5-fluorouracil (or precursor thereof) as cancer treatment.

The invention relates to an ultrasound mediated mucosal drug delivery system which disperses a large quantity of vesicles containing gases and having acoustic response properties into the traditional liquid type mucosal drug delivery formulation through a formulation technology so as to promote drugs inside the liquid type mucosal drug delivery formulation to faster enter deep tissues and blood circulation to develop therapeutic action by penetrating through a mucosa under ultrasound mediation. The ultrasound mediated mucosal drug delivery system has wide application range and can meet the requirements of mucosa deep tissues or systemic therapy.

The invention belongs to the field of pharmaceutical preparations, and discloses a hyaluronic acid prodrug as well as a preparation method thereof and application thereof in transdermal delivery. According to the preparation method, hyaluronic acid is used for grafting drug molecules so as to overcome the barrier function of stratum corneum, and the drug molecules are transmitted to the subcutaneous tissues by means of intercellular space penetration and an opening of cutaneous appendages, so that drug molecular targeting and skin absorption efficiency are improved. As a carrier for administration, hyaluronic acid can effectively improve the percutaneous permeability of a drug, and helps the drug to be absorbed into the systemic circulation, thereby enabling an effective blood concentration of local or systemic treatment to be reached. Compared with the prior art, the hyaluronic acid prodrug enables the skin penetration amount of the drug molecules to be obviously increased so as to increase the utilization rate of the drug; furthermore, the hyaluronic acid prodrug facilitates the treatment of a doctor for a patient, can realize direct administration for certain diseases, and effectively reduces risks and side effects, thus having a broad application prospect.

Systemic delivery of Modafinil to the nasal mucous membrane elicits rapid systemic therapeutic response with reduced side effects compared to current methods of administration.

The invention discloses application of an ferroptosis inhibitor as an active ingredient in preparation of a drug for treating systemic lupus erythematosus. Researches find that neutrophils of an SLE patient spontaneously generate ferroptosis, and the neutrophils return to normal after effective systemic treatment. The ferroptosis inhibitor liproxstatin-1 (LPX-1) can be used for delaying the deathrate of neutrophils and inhibiting ferroptosis. The Crispr / cas9 technology demonstrates that increased ferroptosis can enable C57 / B6 mice to spontaneously develop lupus phenotype. In an MRL / lpr mice model, the LPX-1 treatment can slow down the progress of lupus diseases, and the spleen, lymph node size, nephritis and proteinuria levels, deposition of renal immune complexes, and levels of inflammatory factors in the treated mice are similar to those in the cyclophosphamide-treated group, indicating that the treatment effect of LPX-1 is similar to that of cyclophosphamide. Due to different action mechanisms, the LPX-1 does not have cytotoxicity similar to cyclophosphamide, so that the LPX-1 can be a better lupus treatment drug.